Top

Clinical Reviews in Allergy & Immunology

Published in:

01-12-2012

Systemic Lupus Erythematosus, Progressive Multifocal Leukoencephalopathy, and T-CD4+ Lymphopenia

Authors: Mariana Brandão, Joana Damásio, António Marinho, Ana Martins da Silva, Júlia Vasconcelos, Esmeralda Neves, Isabel Almeida, Fátima Farinha, Carlos Vasconcelos

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2012

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection caused by the reactivation of JC virus and occurs in patients with severe primary or secondary immunosuppression. Recently, PML is becoming relevant in autoimmune disorders, particularly in patients treated with biologic agents. However, systemic lupus erythematosus (SLE) appears to be associated with susceptibility to PML that cannot be entirely explained by the immunosuppressive therapy. The authors present two patients with the diagnosis of SLE and PML: One had a heavy immunosuppressive therapy history, and the other had never experienced biologic or cytotoxic therapeutics. Both patients had a profound T-CD4+ lymphopenia during their clinical history. These two cases emphasize the importance of CD4+ lymphopenia in SLE patients with and without immunosuppressors regarding opportunistic infections.

Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35–47PubMedCrossRef

Palazzo E, Yahia SA (2012) Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine. doi:10.1016/j.jbspin.2011.11.002

Molloy ES, Calabrese LH (2009) Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60:3761–3765PubMedCrossRef

Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J (2010) Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 75:1326–1332PubMedCrossRef

Calabrese LH, Molloy ES, Huang DR, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases. Arthritis Rheum 56:2116–2128PubMedCrossRef

Molloy ES, Calabrese LH (2008) Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8:144–146PubMedCrossRef

Molloy ES (2011) PML and rheumatology: the contribution of disease and drugs. Cleve Clin J Med 78(Suppl 2):S28–S32PubMedCrossRef

Graff-Radford J, Robinson MT, Warsame RM, Matteson EL, Eggers SD, Keegan BM (2012) Progressive multifocal leukoencephalopathy in a patient treated with etanercept. Neurologist 18:85–87PubMedCrossRef

Gonçalves FG, Lamb L, Del Carpio-O'Donovan R (2011) Progressive multifocal leukoencephalopathy restricted to the posterior fossa in a patient with systemic lupus erythematosus. Braz J Infect Dis 15:609–612PubMed

10.

Pavlovic AM, Bonaci-Nikolic B, Kozic D et al (2012) Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 21:100–102PubMedCrossRef

11.

Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. doi:10.1002/art.34468

12.

Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME (2008) The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30:90–98PubMedCrossRef

13.

White MK, Khalili K (2011) Pathogenesis of progressive multifocal leukoencephalopathy—revisited. J Infect Dis 203:578–586PubMedCrossRef

14.

Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO (1996) JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 70:7004–7012PubMed

15.

Koralnik IJ (2006) Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 60:162–173PubMedCrossRef

16.

Houff SA, Major EO, Katz DA et al (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318:301–305PubMedCrossRef

17.

Tan CS, Dezube BJ, Bhargava P et al (2009) Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 199:881–888PubMedCrossRef

18.

Du Pasquier RA, Autissier P, Zheng Y, Jean-Jacques J, Koralnik IJ (2005) Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 19:2069–2076PubMedCrossRef

19.

Koralnik IJ, Du Pasquier RA, Kuroda MJ et al (2002) Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168:499–504PubMed

20.

Shah R, Bag AK, Chapman PR, Curé JK (2010) Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 65:431–439PubMedCrossRef

21.

Pelosini M, Focosi D, Rita F et al (2008) Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 87:405–412PubMedCrossRef

22.

Carson KR, Evens AAM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834–4840PubMedCrossRef

23.

Epker JL, van Biezen P, van Daele PL, van Gelder T, Vossen A, van Saase JL (2009) Progressive multifocal leukoencephalopathy, a review and an extended report of five patients with different immune compromised states. Eur J Intern Med 20:261–267PubMedCrossRef

24.

Ferreira S, Vasconcelos J, Marinho A et al (2009) Linfopenia T CD4 no lupus eritematoso sistémico. Acta Reumatol Port 34:200–206PubMed

25.

Ng WL, Chu CM, Wu AK, Cheng VC, Yuen KY (2006) Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 99:37–47PubMedCrossRef

26.

Narula S, LaRosa DF, Kamoun M, Dalmau J, Levinson AI (2007) Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution. Ann Allergy Asthma Immunol 98:483–489PubMedCrossRef

27.

Angelini L, Pietrogrande MC, Delle Piane MR et al (2001) Progressive multifocal leukoencephalopathy in a child with hyperimmunoglobulin E recurrent infection syndrome and review of literature. Neuropediatrics 32:250–255PubMedCrossRef

28.

Coutinho A, Carneiro-Sampaio M (2008) Primary immunodeficiencies unravel critical aspects of the pathophysiology of autoimmunity and of the genetics of autoimmune disease. J Clin Immunol 28(Suppl 1):S4–S10PubMedCrossRef

29.

Haider S, Nafziger D, Gutirriez JA, Brar I, Mateo N, Fogle J (2000) Progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia: a case report and review of reported cases. Clin Infect Dis 31:e20–e22PubMedCrossRef

30.

Smith DK, Neal JJ, Holmberg DS (1993) Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. N Engl J Med 328:373–379PubMedCrossRef

31.

Patel A, Patel J, Ikwuagwu J (2010) Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 65:2489–2492PubMedCrossRef

32.

Wladis EJ, Kapila R, Chu DS (2005) Idiophatic CD4+ lymphocytopenia and Sjogren syndrome. Arch Ophtalmol 123:1012CrossRef

33.

Berger JR (2010) Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 33:969–983PubMedCrossRef

34.

Clifford DB, Ances B, Costello C et al (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68:1156–1164PubMedCrossRef

35.

Terrier B, Hummel A, Fakhouri F et al (2007) Progressive multifocal leukoencephalopathy in a non-AIDS patient: high efficiency of combined cytarabine and cidofovir. Rev Med Interne 28:488–491PubMedCrossRef

36.

Geschwind MD, Skolasky RI, Royal WS, McArthur JC (2001) The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 7:353–357PubMedCrossRef

37.

Royal W 3, Dupont B, McGuire D (2003) Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 9:411–419

38.

O’Reilly S (1997) Efficacy of camptothecin in progressive multifocal leukoencephalopathy. Lancet 350:291PubMedCrossRef

39.

Marzocchetti A, Tompkins T, Clifford DB et al (2009) Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73:1551–1558PubMedCrossRef

40.

Elphick GF, Querbes W, Jordan JA et al (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380–1383PubMedCrossRef

Title: Systemic Lupus Erythematosus, Progressive Multifocal Leukoencephalopathy, and T-CD4+ Lymphopenia
Authors: Mariana Brandão
Joana Damásio
António Marinho
Ana Martins da Silva
Júlia Vasconcelos
Esmeralda Neves
Isabel Almeida
Fátima Farinha
Carlos Vasconcelos
Publication date: 01-12-2012
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 3/2012
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-012-8327-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Antineutrophil Cytoplasmic Autoantibodies: How Are They Detected and What Is Their Use for Diagnosis, Classification and Follow-up?

Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease

Impact of Hallmark Autoantibody Reactivity on Early Diagnosis in Scleroderma

Immunological Orchestration of Liver Fibrosis

Treatment of ANCA-Associated Vasculitis, Where to Go?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials